Acura Pharmaceuticals ( (ACUR) ) has released a notification of late filing.
Acura Pharmaceuticals has announced a delay in filing its Form 10-K (Yearly Report) for the financial period ending December 31, 2024. The primary reason for the delay is the company’s liquidity issues, which have affected its ability to meet day-to-day operational obligations. Acura Pharmaceuticals is currently seeking funding solutions and is dependent on loans from Abuse Deterrent Pharma, LLC. The company has also faced challenges due to a change in its independent registered public accounting firm, which was appointed in February 2024. Acura Pharmaceuticals expects to file the delayed report within the fifteen-day extension period allowed under SEC rules. Despite the delay, the company does not anticipate any significant changes in its financial results compared to the previous fiscal year. The company is actively working on compliance efforts, and the notification was signed by Robert A. Seiser, Senior VP & CFO, on March 26, 2025.
More about Acura Pharmaceuticals
YTD Price Performance: -5.00%
Average Trading Volume: 9,200
Technical Sentiment Signal: Buy
Current Market Cap: $1.31M
Learn more about ACUR stock on TipRanks’ Stock Analysis page.